Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Urinary Bladder Neoplasms × lirilumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1 Neoplasms 1 Multiple Myeloma 1 Advanced Cancer 1

Interventions

pembrolizumab 24 Gemcitabine 17 Nivolumab 10 Cisplatin 10 Docetaxel 8 Paclitaxel 7 atezolizumab 6 Carboplatin 6 durvalumab 5 Radiotherapy 5 fludarabine 3 enfortumab vedotin 3 Magnetic Resonance Spectroscopy 3 Ipilimumab 3 Fluorouracil 3 Cyclophosphamide 3 vocimagene amiretrorepvec 2 tremelimumab 2 poly ICLC 2 infigratinib 2 erdafitinib 2 cc-486 2 belinostat 2 amminedichloro(2-methylpyridine)platinum(II) 2 aflibercept 2 Vorinostat 2 Trastuzumab 2 Taxes 2 Suramin 2 Specimen Handling 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03532451 2024-09-19

PrE0807

PrECOG, LLC.

Phase 1 Completed

43 enrolled 15 charts

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡